- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04615845
A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC
Um estudo aberto, de centro único, de fase 1 para avaliar a segurança da imunoterapia contra o câncer com células dendríticas autólogas em pacientes com câncer de próstata metastático resistente à castração (mCRPC)
The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Seoul, Coréia do Sul
- Asan medical center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
19 and under 80 years
-
Histologically confirmed prostate adenocarcinoma
-
Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases
-
Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone <50 ng/dL) and If either a or b is satisfied:
- Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
- Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
-
Asymptomatic or mild patients after previous treatment
- Patients who have not used narcotic analgesics within 21 days prior to enrollment
- Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
-
Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed
-
Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1
-
Patients whose life expectancy is at least 6 months or longer
-
Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3
-
Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance > 30mL/min
-
Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) <2.5 x ULN
-
Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects
-
Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period
-
Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)
Exclusion Criteria:
- Patients who have a local recurrence and are scheduled for local treatment.
- Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
- Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
- Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
- Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)
- Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
- Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
- Patients with a history of organ or hematopoietic stem cell transplantation
- Patients with acute or chronic infections requiring systemic treatment
- Patients known to be infected with human immunodeficiency virus (HIV)/serum positive
- Patients with active hepatitis A, B or C
- Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
- Patients expected to require therapeutic biotherapy or immunotherapy
- Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
- Patients with a history of anaphylaxis to gentamicin
- Others, if the person in charge of the study determines that it is not suitable for the clinical trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cellgram-DC-PC
Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes. |
Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse Event
Prazo: From informed consent to the end of treatment at Week 28.
|
Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
From informed consent to the end of treatment at Week 28.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Immune Response
Prazo: At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product. |
At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
|
Change in Prostate-Specific Antigen (PSA)
Prazo: At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment. |
At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: BUMJIN LIM, Ph.D, Asan Medical Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PMC-DC-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be made available to other researchers.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .